Impact of Vitamin D3 Supplementation on Cancer Progression and Survival Rates among Vitamin D-Deficient Cancer Patients: A Multicenter Randomized Controlled Trial
DOI:
https://doi.org/10.64229/84bvr683Keywords:
Vitamin D3, Cancer progression, Survival rate, Oncology, Randomized controlled trial, Vitamin D deficiency, Tumor microenvironmentAbstract
Background: Evidence linking vitamin D status with cancer outcomes is biologically plausible, but clinical findings remain inconsistent. Objective: To evaluate whether vitamin D3 supplementation affects cancer progression and survival in vitamin D-deficient patients. Methods: In this multicenter randomized controlled trial, 500 adults aged 18-75 years with a confirmed malignancy and serum 25-hydroxyvitamin D below 30 ng/mL were enrolled at five oncology centers in Khyber Pakhtunkhwa, Pakistan. Participants received vitamin D3 (2000-2200 IU/day) plus standard care or standard care alone. Outcomes included serum vitamin D, cancer progression according to RECIST 1.1, overall survival, tumor response, and associations between vitamin D change and clinical outcomes. Analyses included Kaplan-Meier methods, Cox regression, and Pearson correlation. Results: Mean serum vitamin D increased from 12.5 to 33.5 ng/mL in the intervention group (p < 0.01). Patients who achieved levels above 30 ng/mL had survival rates of 85-95% (95% CI: 82.3-97.2%), compared with 70% (95% CI: 65.4-74.6%) among severely deficient patients. Vitamin D change correlated with survival time (r = 0.72, p = 0.01), and progression-free survival favored supplementation (log-rank p < 0.01). Benefits were consistent across the evaluated cancer types (interaction p = 0.28). Conclusion: In vitamin D-deficient patients receiving cancer treatment, vitamin D3 supplementation corrected deficiency and was associated with slower progression and better survival. These findings support further confirmatory trials before routine oncologic adoption. Clinical Trial Registration: NCT05621746; registered November 14, 2022.
References
[1]Zhang R, Naughton DP. Vitamin D in health and disease: Current perspectives. Nutrition Journal, 2010, 9, 65. DOI: 10.1186/1475-2891-9-65
[2]Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Experimental and Therapeutic Medicine, 2011, 2, 181-193. DOI: 10.3892/etm.2011.205
[3]Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: A meta-analysis. British Journal of Cancer, 2014, 111, 976-980. DOI: 10.1038/bjc.2014.294
[4]Zhang R, Zhang Y, Liu Z, Pei Y, Xu P, Chong W, et al. Association between vitamin D supplementation and cancer mortality: A systematic review and meta-analysis. Cancers (Basel), 2022, 14(15), 3717. DOI: 10.3390/cancers14153717
[5]Amiri M. Vitamin D and cancer: A contradictory problem. Immunopathologia Persa, 2018, 4(2), e13. DOI: 10.15171/ipp.2018.13
[6]Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Hilary F, et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocrine Reviews, 2008, 29(6),726-776. DOI: 10.1210/er.2008-0004
[7]Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, et al. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. Journal of Bone and Mineral Research, 1998, 13(3), 325-349. DOI: 10.1359/jbmr.1998.13.3.325
[8]Hsieh JC, Shimizu Y, Minoshima S, Shimizu N, Haussler CA, Jurutka PW, et al. Novel nuclear localization signal between the two DNA-binding zinc fingers in the human vitamin D receptor. Journal of Cellular Biochemistry, 1998, 70(1), 94-109. DOI: 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.0.CO;2-B
[9]Michigami T, Suga A, Yamazaki M, Shimizu C, Cai G, Okada S, et al. Identification of amino acid sequence in the hinge region of human vitamin D receptor that transfers a cytosolic protein to the nucleus. Journal of Biological Chemistry, 1999, 274(47), 33531-33538. DOI: 10.1074/jbc.274.47.33531
[10]Yasmin R, Williams RM, Xu M, Noy N. Nuclear import of the retinoid X receptor, the vitamin D receptor, and their mutual heterodimer. Journal of Biological Chemistry, 2005, 280(48), 40152-40160. DOI: 10.1074/jbc.M507708200
[11]Hsieh JC, Jurutka PW, Galligan MA, Terpening CM, Haussler CA, Samuels DS, et al. Human vitamin D receptor is selectively phosphorylated by protein kinase C on serine 51, a residue crucial to its trans-activation function. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88(20), 9315-9319. DOI: 10.1073/pnas.88.20.9315
[12]Jurutka PW, Hsieh JC, MacDonald PN, Terpening CM, Haussler CA, Haussler MR, et al. Phosphorylation of serine 208 in the human vitamin D receptor. Journal of Biological Chemistry, 1993, 268(9), 6791-6799. DOI: 10.1016/S0021-9258(18)53319-6
[13]Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects. Physiological Reviews, 2016, 96(1), 365-408. DOI: 10.1152/physrev.00014.2015
[14]Heaney RP. Vitamin D in health and disease. Clinical Journal of the American Society of Nephrology, 2008, 3(5), 1535-1541. DOI: 10.2215/CJN.01160308
[15]Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. Journal of Lipid Research, 2014, 55(1), 13-31. DOI: 10.1194/jlr.R031534
[16]Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochimica et Biophysica Acta, 2011, 1814(1), 186-199. DOI: 10.1016/j.bbapap.2010.06.022
[17]Takeyama KI, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science, 1997, 277(5333), 1827-1830. DOI: 10.1126/science.277.5333.1827
[18]Brenza HL, DeLuca HF. Regulation of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3. Archives of Biochemistry and Biophysics, 2000, 381(1), 143-152. DOI: 10.1006/abbi.2000.1970
[19]Hewison M, Zehnder D, Bland R, Stewart P. 1alpha-Hydroxylase and the action of vitamin D. Journal of Molecular Endocrinology, 2000, 25(2), 141-148. DOI: 10.1677/jme.0.0250141
[20]Murayama A, Takeyama KI, Kitanaka S, Kodera Y, Hosoya T, Kato S, et al. The promoter of the human 25-hydroxyvitamin D3 1alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1alpha,25(OH)2D3. Biochemical and Biophysical Research Communications, 1998, 249(1), 11-16. DOI: 10.1006/bbrc.1998.9098
[21]Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nature Reviews Cancer, 2007, 7(9), 684-700. DOI: 10.1038/nrc2196
[22]Haussler MR, Jurutka PW, Mizwicki M, Norman AW. Vitamin D receptor-mediated actions of 1alpha,25-dihydroxyvitamin D3: Genomic and non-genomic mechanisms. Best Practice & Research Clinical Endocrinology & Metabolism, 2011, 25,(4), 543-559. DOI: 10.1016/j.beem.2011.05.010
[23]Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, et al. Molecular mechanisms of vitamin D action. Calcified Tissue International, 2013, 92(2), 77-98. DOI: 10.1007/s00223-012-9619-0
[24]Sannappa Gowda NG, Shiragannavar VD, Puttahanumantharayappa LD, Shivakumar AT, Dallavalasa S, Basavaraju CG, et al. Quercetin activates vitamin D receptor and ameliorates breast cancer induced hepatic inflammation and fibrosis. Frontiers in Nutrition, 2023, 10, 1158633. DOI: 10.3389/fnut.2023.1158633
[25]Pike JW, Meyer MB. Fundamentals of vitamin D hormone-regulated gene expression. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144 Pt A, 5-11. DOI: 10.1016/j.jsbmb.2013.11.004
[26]Nemere I, Safford SE, Rohe B, DeSouza MM, Farach-Carson MC. Identification and characterization of 1,25D3-membrane-associated rapid response steroid binding protein. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90(1-5), 281-285. DOI: 10.1016/j.jsbmb.2004.03.031
[27]Giammanco M, Di Majo D, La Guardia M, Aiello S, Crescimannno M, Flandina C, et al. Vitamin D in cancer chemoprevention. Pharmaceutical Biology, 2015, 53(10), 1399-1434. DOI: 10.3109/13880209.2014.988274
[28]Zeeb H. Vitamin D and cancer prevention. Current Nutrition Reports, 2012, 1, 24-29. DOI: 10.1007/s13668-011-0005-8
[29]Muñoz A, Grant WB. Vitamin D and cancer: An historical overview of the epidemiology and mechanisms. Nutrients, 2022, 14(7), 1448. DOI: 10.3390/nu14071448
[30]Arayici ME, Basbinar Y, Ellidokuz H. Vitamin D intake, serum 25-hydroxyvitamin D levels, and cancer risk: A comprehensive meta-meta-analysis. Nutrients, 2023, 15(12), 2722. DOI: 10.3390/nu15122722
[31]Sha S, Chen LJ, Brenner H, Schöttker B. Associations of 25-hydroxyvitamin D status and vitamin D supplementation use with mortality due to 18 frequent cancer types in the UK Biobank cohort. European Journal of Cancer, 2023, 191, 113241. DOI: 10.1016/j.ejca.2023.113241
[32]Li J, Zhang H, Zhu H, Dai Z. 25-Hydroxyvitamin D concentration is positively associated with overall survival in advanced pancreatic cancer: A systematic review and meta-analysis. Nutrition Research, 2023, 117, 73-82. DOI: 10.1016/j.nutres.2023.07.001
[33]Kim Y, Chang Y, Cho Y, Chang J, Kim K, Park DI, et al. Serum 25-hydroxyvitamin D levels and risk of colorectal cancer: An age-stratified analysis. Gastroenterology, 2023, 165(4), 920-931. DOI: 10.1053/j.gastro.2023.06.029
[34]Wang YF, Li L, Deng XQ, Fang YJ, Zhang CX. Association of DNA methylation of vitamin D metabolic pathway related genes with colorectal cancer risk. Clinical Epigenetics, 2023, 15(1), 140. DOI: 10.1186/s13148-023-01555-0
[35]Chen X, Song S, Shi J, Wang Z, Song W, Wang J, et al. Evaluating the effect of body mass index and 25-hydroxy-vitamin D level on basal cell carcinoma using Mendelian randomization. Scientific Reports, 2023, 13(1), 16552. DOI: 10.1038/s41598-023-43926-w
[36]Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. The role of vitamin D in cancer prevention. American Journal of Public Health, 2006, 96(2), 252-261. DOI: 10.2105/AJPH.2004.045260
[37]Izurieta-Pacheco AC, Sangros-Gimenez A, Martinez-Garcia E, Perez-Jaume S, Mora J, Gorostegui-Obanos M,et al. Vitamin D status in children with high-risk neuroblastoma. Journal of Pediatric Hematology/Oncology, 2023, 45(8), e953-e958. DOI: 10.1097/MPH.0000000000002762
[38]Rahman ST, Waterhouse M, Pham H, Duarte Romero B, Baxter C, McLeod DSA, et al. Effects of vitamin D supplementation on telomere length: An analysis of data from the randomised controlled D-Health Trial. Journal of Nutrition, Health and Aging, 2023, 27(8), 609-616. DOI: 10.1007/s12603-023-1948-3
[39]Manocha A, Brockton NT, Cook L, Kopciuk KA. Low serum vitamin D associated with increased tumor size and higher grade in premenopausal Canadian women with breast cancer. Clinical Breast Cancer, 2023, 23(6), e368-e376. DOI: 10.1016/j.clbc.2023.06.003
[40]Reber E, Gomes F, Vasiloglou MF, Schuetz P, Stanga Z. Nutritional risk screening and assessment. Journal of Clinical Medicine, 2019, 8(7), 1065. DOI: 10.3390/jcm8071065
[41]Qadir J, Majid S, Khan MS, Wani MD, Naikoo NA. Vitamin D receptor gene variations and their haplotypic association: Possible impact on gastric cancer risk. Journal of Cancer Research and Therapeutics, 2023, 19(5), 1115-1125. DOI: 10.4103/jcrt.jcrt_1479_21
[42]Cheema HA, Fatima M, Shahid A, Bouaddi O, Elgenidy A, Rehman AU, et al. Vitamin D supplementation for the prevention of total cancer incidence and mortality: An updated systematic review and meta-analysis. Heliyon. 2022, 8(11), e11290. DOI: 10.1016/j.heliyon.2022.e11290
[43]Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: Clinical aspects. Best Practice & Research Clinical Endocrinology & Metabolism, 2011, 25(4), 605-615. DOI: 10.1016/j.beem.2011.06.006
[44]Li M, Chen P, Li J, Chu R, Xie D, Wang H. The impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: A systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism, 2014, 99(7), 2327-2336. DOI: 10.1210/jc.2013-4320
[45]Tretli S, Schwartz GG, Torjesen PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: A population-based study. Cancer Causes Control, 2012, 23(2), 363-370. DOI: 10.1007/s10552-011-9885-6
[46]Robsahm TE, Tretli S, Torjesen PA, Babigumira R, Schwartz GG. Serum 25-hydroxyvitamin D levels predict cancer survival: A prospective cohort with measurements prior to and at the time of cancer diagnosis. Clinical Epidemiology, 2019, 11, 695-705. DOI: 10.2147/CLEP.S207230
[47]Hernandez-Alonso P, Boughanem H, Canudas S, Becerra-Tomás N, Fernández de la Puente M, Babio N, et al. Circulating vitamin D levels and colorectal cancer risk: A meta-analysis and systematic review of case-control and prospective cohort studies. Critical Reviews in Food Science and Nutrition, 2023, 63(1), 1-17. DOI: 10.1080/10408398.2021.1939649
[48]McCullough ML, Zoltick ES, Weinstein SJ, Fedirko V, Wang M, Cook NR, et al. Circulating vitamin D and colorectal cancer risk: An international pooling project of 17 cohorts. Journal of the National Cancer Institute, 2019, 111(2), 158-169. DOI: 10.1093/jnci/djy087
[49]Henn M, Martin-Gorgojo V, Martin-Moreno JM. Vitamin D in cancer prevention: Gaps in current knowledge and room for hope. Nutrients, 2022, 14(21), 4512. DOI: 10.3390/nu14214512
[50]Poole EM, Shu X, Caan BJ, Flatt SW, Holmes MD, Lu W, et al. Postdiagnosis supplement use and breast cancer prognosis in the after breast cancer pooling project. Breast Cancer Research and Treatment, 2013, 139(2), 529-537. DOI: 10.1007/s10549-013-2548-4
[51]Zeichner SB, Koru-Sengul T, Shah N, Liu Q, Markward NJ, Montero AJ, et al. Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clinical Breast Cancer, 2015, 15(1), e1-e11. DOI: 10.1016/j.clbc.2014.08.001
[52]Yokosawa EB, Arthur AE, Rentschler KM, Wolf GT, Rozek LS, Mondul AM. Vitamin D intake and survival and recurrence in head and neck cancer patients. Laryngoscope, 2018, 128(11), E371-E376. DOI: 10.1002/lary.27256
[53]Mulpur BH, Nabors LB, Thompson RC, Olson JJ, LaRocca RV, Thompson Z, et al. Complementary therapy and survival in glioblastoma. Neuro-Oncology Practice, 2015, 2(3), 122-126. DOI: 10.1093/nop/npv008
[54]Madden JM, Murphy L, Zgaga L, Bennett K. De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival. Breast Cancer Research and Treatment, 2018, 172(1), 179-190. DOI: 10.1007/s10549-018-4896-6
[55]Kim H, Lipsyc-Sharf M, Zong X, Wang X, Hur J, Song M, et al. Total vitamin D intake and risks of early-onset colorectal cancer and precursors. Gastroenterology, 2021, 161(4), 1208-1217.e9. DOI: 10.1053/j.gastro.2021.07.002
[56]Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. American Journal of Clinical Nutrition, 2007, 85(6), 1586-1591. DOI: 10.1093/ajcn/85.6.1586
[57]Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: A reanalysis of the Women's Health Initiative limited-access data set. American Journal of Clinical Nutrition, 2011, 94(4), 1144-1149. DOI: 10.3945/ajcn.111.015032
[58]Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, et al. Effect of vitamin D and calcium supplementation on cancer incidence in older women: A randomized clinical trial. JAMA, 2017, 317(12), 1234-1243. DOI: 10.1001/jama.2017.2115
[59]Zgaga L. Heterogeneity of the effect of vitamin D supplementation in randomized controlled trials on cancer prevention. JAMA Network Open, 2020, 3(11), e2027176. DOI: 10.1001/jamanetworkopen.2020.27176
[60]Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. New England Journal of Medicine, 2019, 380(1), 33-44. DOI: 10.1056/NEJMoa1809944
[61]Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. Journal of the National Cancer Institute, 2008, 100(22), 1581-1591. DOI: 10.1093/jnci/djn360
[62]Keum N, Lee DH, Greenwood DC, Manson JE, Giovannucci E. Vitamin D supplementation and total cancer incidence and mortality: A meta-analysis of randomized controlled trials. Annals of Oncology, 2019, 30(5), 733-743. DOI: 10.1093/annonc/mdz059
[63]Virtanen JK, Nurmi T, Aro A, Bertone-Johnson ER, Hyppönen E, Kröger H, et al. Vitamin D supplementation and prevention of cardiovascular disease and cancer in the finnish vitamin D trial: A randomized controlled trial. American Journal of Clinical Nutrition, 2022, 115(5), 1300-1310. DOI: 10.1093/ajcn/nqab419
[64]Bouillon R. Comparative analysis of nutritional guidelines for vitamin D. Nature Reviews Endocrinology, 2017, 13(8), 466-479. DOI: 10.1038/nrendo.2017.31
[65]Mead MN. Benefits of sunlight: A bright spot for human health. Environmental Health Perspectives, 2008, 116(4), A160-A167. DOI: 10.1289/ehp.116-a160
[66]Freedman DM, Dosemeci M, McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: A composite death certificate based case-control study. Occupational & Environmental Medicine, 2002, 59(4), 257-262. DOI: 10.1136/oem.59.4.257
[67]Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW. Vitamin D and colorectal, breast, and prostate cancers: A review of the epidemiological evidence. Journal of Cancer, 2016, 7(3), 232-240. DOI: 10.7150/jca.13403
[68]Colston K, Colston MJ, Feldman D. 1,25-Dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology, 1981, 108(3), 1083-1086. DOI: 10.1210/endo-108-3-1083
[69]Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, et al. Serum vitamin D concentration and prostate cancer risk: A nested case-control study. Journal of the National Cancer Institute, 2008, 100(11), 796-804. DOI: 10.1093/jnci/djn152
[70]Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, et al. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clinical Cancer Research, 2006, 12(19)5895-5901. DOI: 10.1158/1078-0432.CCR-06-1039
[71]Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Research, 2009, 69(3), 967-975. DOI: 10.1158/0008-5472.CAN-08-2307
[72]Colston K, James S, Ofori-Kuragu E, Binderup L, Grant A. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. British Journal of Cancer, 1997, 76, 1017-1020. DOI: 10.1038/bjc.1997.501
[73]Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1997, 50(6), 999-1006. DOI: 10.1016/S0090-4295(97)00408-1
[74]Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. Journal of Biological Chemistry, 2004, 279(51), 53213-53221. DOI: 10.1074/jbc.M410395200
[75]Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. Journal of Cellular Biochemistry, 2003, 88(2), 363-371. DOI: 10.1002/jcb.10334
[76]Ma Y, Yu WD, Trump DL, Johnson CS. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer, 2010, 116(13), 3294-3303. DOI: 10.1002/cncr.25059
[77]Nakagawa K, Kawaura A, Kato S, Takeda E, Okano T. 1alpha,25-Dihydroxyvitamin D3 is a preventive factor in the metastasis of lung cancer. Carcinogenesis, 2005, 26(2), 429-440. DOI: 10.1093/carcin/bgh332
[78]Zhang X, Jiang F, Li P, Li CR; Ma QP; Nicosia SV, et al. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clinical Cancer Research, 2005, 11(1), 323-328. DOI: 10.1158/1078-0432.323.11.1
[79]Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annual Review of Pharmacology and Toxicology, 2011, 51, 311-336. DOI: 10.1146/annurev-pharmtox-010510-100611
[80]Reitsma PH, Rothberg PG, Astrin SM, Trial J, Bar-Shavit Z, Hall A, et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature, 1983, 306, 492-494. DOI: 10.1038/306492a0
[81]Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: A review of molecular mechanisms. Biochemical Journal, 2012, 441(1), 61-76. DOI: 10.1042/BJ20110744
[82]Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Research, 2005, 65(17), 7917-7925. DOI: 10.1158/0008-5472.CAN-05-1435
[83]Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell, 2014, 159(1), 80-93. DOI: 10.1016/j.cell.2014.08.007
[84]Swami S, Krishnan AV, Williams J, Aggarwal A, Albertelli MA, Horst RL, et al. Vitamin D mitigates the adverse effects of obesity on breast cancer in mice. Endocrine-Related Cancer, 2016, 23(4), 251-264. DOI: 10.1530/ERC-15-0557
[85]Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: Global perspective. Annals of Epidemiology, 2009, 19(7), 468-483. DOI: 10.1016/j.annepidem.2009.03.021
[86]James SY, Mackay AG, Colston KW. Effects of 1,25-dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 1996, 58(4), 395-401. DOI: 10.1016/0960-0760(96)00048-9
[87]Bao BY, Yao J, Lee YF. 1alpha,25-Dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis, 2006, 27(9), 1883-1893. DOI: 10.1093/carcin/bgl041
[88]Li H, Stampfer MJ, Hollis BW, Mucci LA, Gaziano JM, Hunter D, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Medicine, 2007, 4(3), e103. DOI: 10.1371/journal.pmed.0040103
[89]Hossein-nezhad A, Spira A, Holick MF. Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: A randomized double-blind clinical trial. PLoS One, 2013, 8(3), e58725. DOI: 10.1371/journal.pone.0058725
[90]Pereira F, Larriba MJ, Muñoz A. Vitamin D and colon cancer. Endocrine-Related Cancer, 2012, 19(3), R51-R71. DOI: 10.1530/ERC-11-0388
[91]Martinez-Reza I, Diaz L, Barrera D, Segovia-Mendoza M, Pedraza-Sánchez S, Soca-Chafre G, et al. Calcitriol inhibits the proliferation of triple-negative breast cancer cells through a mechanism involving the proinflammatory cytokines IL-1beta and TNF-alpha. Journal of Immunology Research, 2019, 6384278. DOI: 10.1155/2019/6384278
[92]Krishnan AV, Swami S, Feldman D. Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: importance of mammary CYP27B1 for treatment and prevention. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 289-295. DOI: 10.1016/j.jsbmb.2012.08.005
[93]Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nature Reviews Cancer, 2014, 14(5), 342-357. DOI: 10.1038/nrc3691
[94]Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103(3-5), 316-321. DOI: 10.1016/j.jsbmb.2006.12.078
[95]Tangpricha V, Flanagan JN, Whitlatch LW, Tseng CC, Chen TC, Holt PR, et al. 25-Hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet, 2001, 357(9269), 1673-1674. DOI: 10.1016/S0140-6736(00)04831-5
[96]Hewison M, Kantorovich V, Liker HR, Van Herle AJ, Cohan P, Zehnder D, et al. Vitamin D-mediated hypercalcemia in lymphoma: Evidence for hormone production by tumor-adjacent macrophages. Journal of Bone and Mineral Research, 2003, 18(3), 579-582. DOI: 10.1359/jbmr.2003.18.3.579
[97]Maestro MA, Molnár F, Carlberg C. Vitamin D and its synthetic analogues. Journal of Medicinal Chemistry, 2019, 62(15), 6854-6875. DOI: 10.1021/acs.jmedchem.9b00208
[98]Leyssens C, Verlinden L, Verstuyf A. The future of vitamin D analogs. Frontiers in Physiology, 2014, 5, 122. DOI: 10.3389/fphys.2014.00122
[99]Duffy MJ, Murray A, Synnott NC, O'Donovan N, Crown J. Vitamin D analogues: Potential use in cancer treatment. Critical Reviews in Oncology/Hematology, 2017, 112, 190-197. DOI: 10.1016/j.critrevonc.2017.02.015
[100]Kuznia S, Zhu A, Akutsu T, Buring JE, Camargo CA Jr, Cook NR, et al. Efficacy of vitamin D3 supplementation on cancer mortality: Systematic review and individual patient data meta-analysis of randomized controlled trials. Ageing Research Reviews, 2023, 87, 101923. DOI: 10.1016/j.arr.2023.101923
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Tariq Hassan, Ali Shaan, Kashif Nawaz, Iftikhar Ahmad, Inayat ul Haq, Muhammad Kabir, Abdullah, Murad Ali (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
